HR4993-119

What This Bill Does

This bill changes Medicare coverage rules for home infusion therapies delivered with an external infusion pump. It allows certain home infusion drugs and related supplies to be treated as covered external infusion pump items even when the drug is not otherwise considered appropriate for home use, as long as the FDA-approved label requires administration by or under the supervision of a health care professional and a qualified home infusion therapy supplier can safely administer or supervise the therapy in the patient's home.

The bill targets therapies that are administered intravenously or subcutaneously at least 12 times per year, or at rates that require an external infusion pump. It also requires HHS to make sure patients are notified about cost-sharing differences between receiving the infusion at home and receiving it in another setting. The practical policy choice is to move more Medicare-covered infusion care out of facilities and into the home when a qualified supplier can deliver it safely.

Who Benefits and How

Medicare beneficiaries who need recurring infusion-pump therapy benefit from a clearer path to receive treatment at home instead of traveling to a facility. Qualified home infusion therapy suppliers benefit because Medicare coverage could apply to more drug, supply, administration, and supervision scenarios. Clinicians supervising home infusion benefit from clearer statutory coverage criteria tied to FDA labeling and patient safety. Caregivers benefit when recurring therapy can be delivered in the home. Manufacturers of pump-administered infusion drugs may benefit if broader home coverage increases use of therapies that require clinician administration.

Who Bears the Burden and How

HHS and CMS coverage staff must implement the new category and ensure beneficiary cost-sharing notices compare home and non-home settings. Medicare administrative contractors must process claims under the new criteria and police whether supplier, FDA-label, and frequency requirements are met. Hospitals and outpatient infusion centers may lose some infusion volume if patients shift to home treatment. Qualified home infusion suppliers must meet safety, supervision, and documentation expectations for therapies that previously may have been handled in facilities.

Key Provisions

• Expands Medicare treatment of external infusion-pump drugs and supplies for certain home-use therapies.
• Requires the drug label to call for administration by or under the supervision of a health care professional.
• Requires a qualified home infusion therapy supplier to be able to safely administer or supervise treatment in the home.
• Limits eligibility to therapies administered at least 12 times per year or at pump-dependent infusion rates.
• Directs HHS to notify beneficiaries about cost sharing in home and alternative care settings.